Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

13G Filing: Tangiers Global, Llc and Endonovo Therapeutics Inc. (ENDV)

Page 1 of 5

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
TANGIERS GLOBAL 19,059,779 7. 19,059,779 9. 19,059,779 12. CO Type of Reporting Person (See Instructions) FOOTNOTES Tangiers has rights, under a Convertible Promissory Note, to own an aggregate number of shares of the Issuer s common stock, which, except for a contractual cap on the amount of outstanding shares of the Issuer s common stock that Tangiers may own, could exceed such a cap. Tangiers s ownership cap is 9.99%

Page 1 of 5 – SEC Filing

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

SCHEDULE 13G

 

Under the Securities Exchange Act of
1934

 

(AMENDMENT NO. ___) *

 

Endonovo
Therapeutics, Inc.
(Name of issuer)

 

Common Stock. $.0001 value per share

(Title of class of securities)

29272H201

(CUSIP number)

 

March 20, 2017

(Date of Event Which Requires filing of
this Statement)

Check the appropriate box to designate
the rule pursuant to which this Schedule is filed:

¨ Rule
13d-l (b)
x Rule
13d-l(c)
¨ Rule
13d-l(d)

* The remainder of this cover
page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required in the
remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange
Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all
other provisions of the Act (however, see the Notes).

 

Persons who respond to the collection of information
contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1745 (1-06)

Follow Endonovo Therapeutics Inc. (LON:ENDV)
Trade (LON:ENDV) Now!
Page 1 of 5